FDA And CMS Missions Converge In The Postmarket Arena – FDA’s Gottlieb
This article was originally published in The Gray Sheet
Executive Summary
Development of postmarket studies represents the best opportunity for CMS and FDA to collaborate and streamline the regulatory and reimbursement process, according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD